{"name":"SCYNEXIS","slug":"scynexis","ticker":"SCYX","exchange":"NASDAQ","domain":"scynexis.com","description":"SCYNEXIS, Inc., a biotechnology company, engages in drug development for the treatment and prevention of difficult-to-treat and drug-resistant fungal infections in the United States. The company offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis and for the reduction in the incidence of recurrence. It also develops SCY-247, which is in Phase I clinical trial for the treatment of invasive fungal infections. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.","hq":"Jersey City, NJ","founded":0,"employees":"18","ceo":"David Angulo","sector":"Anti-Infectives / Antifungals","stockPrice":0.76,"stockChange":0,"stockChangePercent":0,"marketCap":"$60M","metrics":{"revenue":20344000,"revenueGrowth":0,"grossMargin":100,"rdSpend":22280000,"netIncome":-8609000,"cash":59263000,"dividendYield":0,"peRatio":-3.5,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"SCY-078 patent cliff ($0.0B at risk)","drug":"SCY-078","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Echinocandin","genericName":"Echinocandin","slug":"echinocandin","indication":"Other","status":"discontinued"},{"name":"PRA","genericName":"PRA","slug":"pra","indication":"Invasive candidiasis","status":"marketed"}]}],"pipeline":[{"name":"Echinocandin","genericName":"Echinocandin","slug":"echinocandin","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"PRA","genericName":"PRA","slug":"pra","phase":"marketed","mechanism":"PRA (prasifungin) is an antifungal agent that inhibits fungal cell wall synthesis by targeting glucan synthase.","indications":["Invasive candidiasis","Invasive aspergillosis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"SCYNEXIS Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"SCYNEXIS reported fourth quarter and full year 2023 financial results, with revenue of $13.4 million and a net loss of $24.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"SCYNEXIS Announces Collaboration with the Bill and Melinda Gates Foundation to Develop Antifungal Therapies","summary":"SCYNEXIS announced a collaboration with the Bill and Melinda Gates Foundation to develop antifungal therapies for the treatment of fungal infections in low- and middle-income countries.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"trial","headline":"SCYNEXIS Announces Positive Topline Results from Phase 2 Clinical Trial of SCY-078","summary":"SCYNEXIS announced positive topline results from a Phase 2 clinical trial of SCY-078, its lead antifungal candidate.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPVGkzQzlvbVJUa215Z3Joc3FrVWc2SnR4a3k2VnJNWDVzeERfalFKMThpODNEOERsejRMZFZzOEc3Tks1T1BlWERkaWZsdmpaOFlOeTFqRk5GQmhBb0RIZGxQWUp5blRtZXR4cG1GbWZaMjBBVk9kbU9CNUhueUNiOEZrWGNzc0k4TzBaRmZ1S2dZU2NOWS1ZampxbWlfdVNpUHdFQmE5d200WDlJUmdIbTYzM2pqbWIwTEgzOE1ScTJaZ3hB?oc=5","date":"2026-03-31","type":"pipeline","source":"BioSpace","summary":"Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million - BioSpace","headline":"Poxel Announces the Sale of PXL770 to Scynexis for a Total Amount of up to $196 Million","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-31","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE5lRlVEYmdQU3RnbGJMVXZMSXNGR1hIT2V1QkpmeFBTMnd4Uk1IZVcwOUFidnRkUTNUb1RySUZjbm9vWHZWNGNTc215Y19uS3N0V0o2SFdWNTduVFJhNjQ4VU9GcFBHZTkyYjN3LU1n?oc=5","date":"2026-03-22","type":"pipeline","source":"Stock Titan","summary":"If You Invested $1,000 in Scynexis (SCYX) - Stock Titan","headline":"If You Invested $1,000 in Scynexis (SCYX)","sentiment":"neutral"},{"date":"2026-03-04","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVkdpejIwdGkxY09DSjhYZF9kVzZRQTBlZllMT0ZOYXFZbWFENVp1cC1MNk9uVzdTNllIMEduVGc2S0dfeDVzd2h2WFo5TG1OdFhWMm5naFNHVG94aGZOb3JZaUR4d1JtSlJxcVVPWlI3Nkh5b0NFb2c0TkxjT2tZWWowVExwUDJpRkc4ZG5nbXBSNXNZdF9GZDU4cVRZQUl2UXB1ZW9aV3NiV3ZYMWlzWV9YQlVMU3hyUmFNcmUyY3RScS1oSF94T09YUmVtZnAzZUg40gHYAUFVX3lxTE4yc2NoQmt2RzFsMnpyazJtekcyU0NOTmVhUEsxZU1nejI1SFpPSXExdTRUdXdRUDdpcjZ1YzBsQkJnaU9LUnlzTW5rMVhDVFdfSHRfcl9hWkhyRDFFN004TEpuRkxsNHhVRFNJR1lRZnBlZndVT2RwcHA5UW90cHpES3l1QzhZSWtFUHNOcHRRRnU4SUpLQ2h1S01KYWVVUEZRMUxQeFVYVjRDbnlsazQzU0FSdWlmdjJRc1lUOFZEeDNVdTktSE1ybVY4cVQ4eFNFMlk3LWNDZA?oc=5","date":"2026-01-23","type":"pipeline","source":"simplywall.st","summary":"Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - simplywall.st","headline":"Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxOODAtbnVKcWl6WTdObG5PYXNWb1h1VnNFNllFT29KLW9RQlhkOU1ybW1jTmZmaGxPVmpqYVZXcnMtM0pweFBGbTU5Z08wd1g0anhoWmllWE9maXlrUEl3R0o5aEZtVFFtUlNFMDBsXzM1UU5WRnktVjNFWXRydWJvZnYwd3dKZEd0T0Y2d3NRYjlDa25KaWpTaWdJOVd6NWE1YWd4Y1hqNWFidmVjald1SjVzYk9KTHRTNlVXMw?oc=5","date":"2025-11-19","type":"pipeline","source":"Stock Titan","summary":"SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan","headline":"SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M","sentiment":"neutral"},{"date":"2025-11-05","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-15","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-08-13","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-07-01","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTE5zOE5jakxrMUdxekw4bnprbjFUZDJTeFQxLUE5YXBFV2VaemlwTWdjNjVHXzZfcWg5MWh3WTd5TEd4dl9fNlBpdGJjZFZKQmVoa3A0VU5pUHBWMHpIMzdXeFcybENoZw?oc=5","date":"2024-05-11","type":"pipeline","source":"MarketBeat","summary":"SCYNEXIS (SCYX) Stock Forecast and Price Target 2026 - MarketBeat","headline":"SCYNEXIS (SCYX) Stock Forecast and Price Target 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxNUWJyWERlQVVZOE44NjVSUmE0NVJWdnNNLXZad0NTZVlwTEduai1paFdJRXhvOVQtQTM2ZVNtbXlDRGJ3anNtZ0cwVHE3T3laZkdQbDhobko4cGFzQ3d1eHVMRG96Z1Q3Q19MRVFFUmktOFJXZDJVTDFWQ3MxSFQ0bGVPdllnRUxnWm9hRDJDRFQyS1Bmdjln?oc=5","date":"2024-04-02","type":"deal","source":"Seeking Alpha","summary":"Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) - Seeking Alpha","headline":"Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE42bzZNdWVGZkhnRGNsZzdOaTBZcGFvaVB0c0lkbGNGeUNyUkx6a19RUzNhYjR3U3ZxX2R4TkFVcVBfWDI1YUFLbk1iQzJaNDB6?oc=5","date":"2024-01-14","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"}],"patents":[{"drugName":"SCY-078","drugSlug":"generic","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"discontinued":1,"marketed":1},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["Gilead Sciences","Merck & Co.","Pfizer Inc."],"therapeuticFocus":["Anti-Infectives","Antifungals"],"financials":{"source":"sec_edgar+yahoo","revenue":257000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":257000,"period":"2017-12-31"},{"value":257000,"period":"2016-12-31"},{"value":257000,"period":"2016-12-31"},{"value":65000,"period":"2016-12-31"},{"value":64000,"period":"2016-09-30"}],"grossProfit":3746000,"grossProfitHistory":[{"period":"2024-12-31","value":3746000},{"period":"2023-12-31","value":124517000},{"period":"2022-12-31","value":4463000},{"period":"2021-12-31","value":12851000}],"rdSpend":22280000,"rdSpendHistory":[{"period":"2025-12-31","value":22280000},{"period":"2024-12-31","value":26405000},{"period":"2023-12-31","value":30928000},{"period":"2022-12-31","value":27259000}],"sgaSpend":14395000,"operatingIncome":-16074000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-16074000},{"period":"2024-12-31","value":-37117000},{"period":"2023-12-31","value":72669000},{"period":"2022-12-31","value":-85757000}],"netIncome":-8609000,"netIncomeHistory":[{"period":"2025-12-31","value":-8609000},{"period":"2024-12-31","value":-21288000},{"period":"2023-12-31","value":67041000},{"period":"2022-12-31","value":-62809000}],"eps":-0.17,"epsHistory":[{"period":"2025-12-31","value":-0.17},{"period":"2024-12-31","value":-0.44},{"period":"2023-12-31","value":1.39},{"period":"2022-12-31","value":-1.47}],"cash":21259000,"cashHistory":[{"period":"2025-12-31","value":21259000},{"period":"2024-12-31","value":16051000},{"period":"2023-12-31","value":34050000},{"period":"2022-12-31","value":45814000}],"totalAssets":59027000,"totalLiabilities":9651000,"totalDebt":2175000,"equity":49376000,"operatingCashflow":-5283000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-5283000},{"period":"2024-12-31","value":-24009000},{"period":"2023-12-31","value":60159000},{"period":"2022-12-31","value":-79883000}],"capex":-9000,"capexHistory":[{"period":"2022-12-31","value":-9000},{"period":"2021-12-31","value":-1172000}],"freeCashflow":-5283000,"dividendsPaid":null,"buybacks":null,"employees":18,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":3580000,"ebit":12258000,"ebitda":12258000,"period":"2025-12-31","revenue":18646000,"epsBasic":null,"netIncome":12258000,"rdExpense":4545000,"epsDiluted":null,"grossProfit":null,"operatingIncome":10521000},{"sga":3287000,"ebit":-8591000,"ebitda":-8591000,"period":"2025-09-30","revenue":334000,"epsBasic":-0.17,"netIncome":-8591000,"rdExpense":5452000,"epsDiluted":-0.17,"grossProfit":null,"operatingIncome":-8405000},{"sga":3784000,"ebit":-6885000,"ebitda":-6885000,"period":"2025-06-30","revenue":1364000,"epsBasic":-0.14,"netIncome":-6885000,"rdExpense":7141000,"epsDiluted":-0.14,"grossProfit":null,"operatingIncome":-9561000},{"sga":3726000,"ebit":-5218000,"ebitda":-5218000,"period":"2025-03-31","revenue":257000,"epsBasic":-0.11,"netIncome":-5391000,"rdExpense":5141000,"epsDiluted":-0.11,"grossProfit":null,"operatingIncome":-8610000},{"sga":4716000,"ebit":-4199000,"ebitda":-4199000,"period":"2024-12-31","revenue":977000,"epsBasic":null,"netIncome":-4433000,"rdExpense":4314000,"epsDiluted":null,"grossProfit":977000,"operatingIncome":-8053000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":-0.06,"netIncome":null,"rdExpense":null,"epsDiluted":-0.06,"grossProfit":660000,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":0.76,"previousClose":0.76,"fiftyTwoWeekHigh":1.31,"fiftyTwoWeekLow":0.56,"fiftyTwoWeekRange":"0.565 - 1.31","fiftyDayAverage":0.93,"twoHundredDayAverage":0.8,"beta":0,"enterpriseValue":3237955,"forwardPE":-3.5,"priceToBook":0.67,"priceToSales":2.95,"enterpriseToRevenue":0.16,"enterpriseToEbitda":0,"pegRatio":0,"ebitda":0,"ebitdaMargin":0,"freeCashflow":2650125,"operatingCashflow":-5919000,"totalDebt":2061000,"debtToEquity":5,"currentRatio":3.94,"returnOnAssets":-21,"returnOnEquity":-53.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":3,"targetMeanPrice":4.19,"targetHighPrice":5.58,"targetLowPrice":3,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2,"institutionHeldPercent":27.7,"sharesOutstanding":79442633,"floatShares":57598292,"sharesShort":2100787,"shortRatio":2.24,"shortPercentOfFloat":2.6,"epsTrailing":-0.48,"epsForward":-0.22,"revenuePerShare":0.4,"bookValue":1.13,"officers":[{"age":60,"name":"Dr. David Gonzalez Angulo M.D.","title":"CEO, President & Director"},{"age":47,"name":"Mr. Scott  Sukenick J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":null,"name":"Ms. Daniella  Gigante","title":"Vice President of Human Resources & Information Technology"}],"industry":"Drug Manufacturers - Specialty & Generic","irWebsite":"","website":"https://www.scynexis.com","phone":"201 884 5485"}}